DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocristals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal …). We are also often engaged for trouble shooting studies on drug products facing unexplained performance issues.